2 weeks Ago By Defense World Staff
HC Wainwright reissued their buy rating on shares of GH Research ( NASDAQ:GHRS – Free Report ) in a research note issued to investors on Wednesday, Benzinga reports. The brokerage currently has a $40.00 price target on the stock.
HC Wainwright also issued estimates for GH Research’s FY2024 earnings at ($0.76) EPS, Q1 2025 earnings at ($0.22) EPS, Q3 2025 earnings at $0.
22 EPS, Q4 2025 earnings at ($0.22) EPS, FY2025 earnings at ($0.88) EPS, FY2026 earnings at ($1.
10) EPS and FY2027 earnings at ($1.18) EPS. Several other equities analysts have also weighed in on the stock.
JMP Securities reissued a “market outperform” rating and issued a $39.00 price objective on shares of GH Research in a research report on Wednesday, September 4th. Canaccord Genuity Group decreased their price target on shares of GH Research from $31.
00 to $28.00 and set a “buy” rating on the stock in a research note on Monday, November 18th. Read Our Latest Stock Report on GH Research GH Research Stock Performance GH Research ( NASDAQ:GHRS – Get Free Report ) last issued its earnings results on Tuesday, September 3rd.
The company reported ($0.20) EPS for the quarter, topping the consensus estimate of ($0.23) by $0.
03. Research analysts forecast that GH Research will post -0.78 earnings per share for the current year.
Institutional Inflows and Outflows An institutional investor recently raised its position in GH Research stock. Lynx1 Capital Management LP lifted its holdings in GH Research PLC ( NASDAQ:GHRS – Free Report ) by 19.8% during the 2nd quarter, according to its most recent disclosure with the SEC.
The institutional investor owned 3,966,726 shares of the company’s stock after acquiring an additional 656,163 shares during the period. GH Research makes up approximately 16.7% of Lynx1 Capital Management LP’s investment portfolio, making the stock its 3rd largest position.
Lynx1 Capital Management LP owned about 7.62% of GH Research worth $46,252,000 at the end of the most recent quarter. Hedge funds and other institutional investors own 56.
90% of the company’s stock. About GH Research ( Get Free Report ) GH Research PLC, together with its subsidiary GH Research Ireland Limited, engages in developing various therapies to treat psychiatric and neurological disorders. It is involved in the development of 5-Methoxy-N,N-Dimethyltryptamine (5-MeO-DMT) therapies for the treatment of patients with treatment-resistant depression (TRD).
Featured Articles Five stocks we like better than GH Research Energy and Oil Stocks Explained Vertiv’s Cool Tech Makes Its Stock Red-Hot How to Use the MarketBeat Stock Screener MarketBeat Week in Review – 11/18 – 11/22 Consumer Discretionary Stocks Explained 2 Finance Stocks With Competitive Advantages You Can’t Ignore Receive News & Ratings for GH Research Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for GH Research and related companies with MarketBeat.com's FREE daily email newsletter ..
